<?xml version="1.0"?>
<Articles JournalTitle="International Journal of Hematology-Oncology and Stem Cell Research">
  <Article>
    <Journal>
      <PublisherName>Tehran University of Medical Sciences</PublisherName>
      <JournalTitle>International Journal of Hematology-Oncology and Stem Cell Research</JournalTitle>
      <Issn>2008-2207</Issn>
      <Volume>13</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="epublish">
        <Year>2019</Year>
        <Month>01</Month>
        <Day>02</Day>
      </PubDate>
    </Journal>
    <title locale="en_US">IL-I&#x3B2; +3954 C / T Polymorphism and Its Clinical Associations in Egyptian Sickle Cell Disease Patients</title>
    <FirstPage>35</FirstPage>
    <LastPage>41</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName>Rasha</FirstName>
        <LastName>Afifi</LastName>
        <affiliation locale="en_US">Department of Pediatrics, Cairo University, Cairo, Egypt</affiliation>
      </Author>
      <Author>
        <FirstName>Yasser</FirstName>
        <LastName>Sedky</LastName>
        <affiliation locale="en_US">Department of Pediatrics, Cairo University, Cairo, Egypt</affiliation>
      </Author>
      <Author>
        <FirstName>Hesham</FirstName>
        <LastName>Abd-Elkarim</LastName>
        <affiliation locale="en_US">Faculty of Medicine, Cairo University, Cairo, Egypt</affiliation>
      </Author>
      <Author>
        <FirstName>Shahira</FirstName>
        <LastName>Botros</LastName>
        <affiliation locale="en_US">Department of Clinical Pathology, Cairo University, Cairo, Egypt</affiliation>
      </Author>
    </AuthorList>
    <History>
      <PubDate PubStatus="received">
        <Year>2018</Year>
        <Month>04</Month>
        <Day>28</Day>
      </PubDate>
      <PubDate PubStatus="accepted">
        <Year>2018</Year>
        <Month>12</Month>
        <Day>24</Day>
      </PubDate>
    </History>
    <abstract locale="en_US">Background: Sickle cell disease (SCD) is a hereditary disorder characterized by hemolytic anemia with different clinical manifestations. Patients with SCD exhibit a chronic inflammatory state and reduced length and quality of life. Interleukin-1 &#x3B2; (IL-1&#x3B2;) is important in acute and chronic diseases; and its single nucleotide polymorphisms (SNP) have been considered as predictors of prognosis in several inflammatory conditions. This study aimed at exploring IL-1&#x3B2; (+3954C/T) SNP as a potential genetic modifier and/or predictor of SCD clinical and laboratory phenotypes.
Materials and Methods: This cross-sectional study involved 50 SCD patients and 50 age, sex and ethnicity-matched healthy individuals. IL-1&#x3B2; (+3954C/T) SNP was identified by PCR-RFLP. Associations between IL-1&#x3B2; (+3954 C/T) SNP and the clinical and laboratory profiles of patients with SCD were studied.
Results: It was found that the homozygous mutant genotype TT was significantly higher in cases compared to controls [13(26%) vs. 3(6%) respectively; p=0.006, OR (95%CI): 5.505(1.460-20.756)]. The homozygous mutant genotype TT was associated with a higher mean pulmonary arterial pressure when compared to the CC and CT genotype (42.62 vs. 33.49 mmHg, p&lt;0.001).
Conclusion: There is an increased prevalence of the mutant genotype of IL-1&#x3B2; +3954 SNP in Egyptian SCD patients. Regarding disease complications, the mutant genotype was more prevalent in cases complicated by pulmonary hypertension. These findings point to the possible role of IL-1&#x3B2; +3954 SNP in the pathophysiology of SCD and its manifestations.</abstract>
    <web_url>https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/941</web_url>
    <pdf_url>https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/941/768</pdf_url>
  </Article>
</Articles>
